Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. (MBOT) announced that ELMNT IR, a multisite outpatient interventional radiology practice in California, signed an order to purchase up to a 12-month supply of LIBERTY Endovascular Robotic System devices.
ELMNT IR became the system’s first Office-Based Laboratory (OBL) customer worldwide to use it. An OBL is an outpatient care setting where physicians perform minimally invasive, image-guided procedures outside traditional hospitals.
Jonathan Steinberger, M.D., co-founder of ELMNT IR and a board-certified interventional radiologist, has performed multiple procedures using LIBERTY, including Y90 mapping, Prostate Artery Embolization and Genicular Artery Embolization. Microbot describes LIBERTY as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical Inc. said its executives and commercial team will attend SIR EDGE 2026 in Louisville, Kentucky, from October 25 through October 27, to engage prospective customers. The event coincides with the Association of Chiefs of Interventional Radiology’s annual fall conference, which the company said offers an opportunity to engage hospital and health-network decisionmakers and continue discussions with Value Analysis Committees. Harel Gadot, chairman, CEO and president, said the team plans to meet physicians and administrators, share user feedback and arrange demonstrations to begin the sales process. Microbot describes LIBERTY as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical Inc. (MBOT) set its 2026 annual meeting for December 14, 2026, with October 15, 2026 as the record date. Qualified proposals under Rule 14a-8 for inclusion in the proxy materials are due by close of business on October 27, 2026.
The company announced several new patent approvals in the U.S., Japan, China and Canada. It reported 44 issued patents and 49 pending patent applications across North America, Europe, Israel and Asia. Microbot said commercial adoption of LIBERTY continues to expand in the U.S. and described market entry in the EU and other jurisdictions as a strategic focus while it pursues a CE Mark.
Microbot Medical Inc. entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System throughout Israel. Microbot reports Israeli Ministry of Health approval through its AMAR Division and registration in the Israeli Medical Device Registry in May 2026.
Microbot anticipates initial orders from Medtechnica during the fourth quarter of 2026. The company describes LIBERTY as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical Inc. (MBOT) disseminated a press release updating certain growth strategies.
Microbot Medical Inc. filed its Form 10-Q for the quarter ended June 30, 2026 and reported that second-quarter revenue and customer counts grew by more than 100% versus the first quarter of 2026, driven by repeat orders, expanded utilization and new customer acquisitions following the Full Market Release of its LIBERTY Endovascular Robotic System in mid-April.
The company expanded adoption of LIBERTY across additional hospital sites and U.S. states, broadened its sales footprint from four to eight sales territories, and entered an agreement with Lovell Government Services Inc. to access more than 2,000 government healthcare facilities. It also partnered with Sanmina to establish a second manufacturing site and achieved a key regulatory milestone as Israel granted marketing clearance, the first jurisdiction outside the U.S. to do so. Management highlighted ongoing cost reduction initiatives aimed at substantially lowering cost of revenue.
Microbot Medical Inc. reported initial commercial revenue from the LIBERTY® Endovascular Robotic System while remaining in a development-stage loss position. For the quarter ended June 30, 2026, revenue was $241,000, all from LIBERTY system sales, and $346,000 for the first half of 2026. Cost of revenues of $884,000 in the quarter and $987,000 year-to-date resulted in negative gross margin as early production and customer concessions weighed on costs.
Research and development expenses were $1.9 million in the quarter and $3.2 million for six months, while sales, general and administrative expenses rose to $3.7 million for the quarter and $6.7 million year-to-date as the company built out commercialization capabilities. Net loss widened to $5.6 million for the quarter and $9.3 million for six months, reflecting higher operating spending and the absence of prior-year one-time other income. Operating cash outflow was $10.0 million in the first half.
Liquidity remains strong, with $67.4 million in cash equivalents and marketable securities as of June 30, 2026 and shareholders’ equity of $68.9 million. Management concludes these resources are sufficient to fund operations for more than 12 months, but the company expects continued losses as it scales LIBERTY manufacturing and sales. Operations and key suppliers are concentrated in Israel, and the company highlights regional conflict as an ongoing risk it is monitoring.
Microbot Medical Inc. updated the compensation terms for its Chief Financial Officer, Rachel Vaknin, by entering into Addendum #4 to her Employment Agreement. The addendum increases her annual base salary to NIS 864,000, described as the equivalent of $288,000 using a presumed 3:1 NIS-to-U.S. dollar exchange rate. The higher salary is effective as of August 1, 2026. The company characterizes this as a material definitive agreement related to executive employment, and the full terms are set out in the addendum referenced as an exhibit.
Microbot Medical Inc. reports that CEO, President and Chairman Harel Gadot will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, Florida, held July 23-26, 2026. He will speak on a “Neurovascular Robotics” panel and present an overview of the endovascular robotic market via livestream.
The company notes recent FDA clearance for its single-use LIBERTY® Endovascular Robotic System, describes growing adoption at leading U.S. academic centers for peripheral endovascular procedures, and highlights winning Surgical Robotics Technology’s Innovative Start-Up Award, which recognizes technologically advanced solutions with potential for broad healthcare impact.
Microbot Medical Inc. reports strong commercial momentum for its LIBERTY Endovascular Robotic System in the second quarter of 2026. The company achieved greater than 100% growth in both revenue and new customers for the quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, as procedure volume also increased.
This performance follows the Full Market Release of the LIBERTY System on April 13, 2026, with new adoptions by leading health systems in several U.S. states. Microbot also expanded distribution through an agreement with Lovell Government Services to access federal healthcare systems. The company grew its U.S. sales footprint from 4 to 8 territories during the quarter and aims for 12 by year-end, received marketing clearance in Israel as its first market outside the U.S., and agreed to establish a second manufacturing site to support rising demand.